Frontline-matched sibling donor transplant of aplastic anemia patients using primed versus steady-state bone marrow grafts
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature..
Priming donors with G-CSF before BM harvest is reported to improve engraftment and GvHD in recipients. These effects are highly desirable when transplanting patients with non-neoplastic hematologic diseases, particularly AA patients. Here we retrospectively report the outcomes of 39 AA patients receiving a primed BM graft from MSD to 43 patients receiving a steady-state BM graft from MSD, otherwise transplanted using a uniform transplant platform. The graft had higher TNC and CD34 cell concentrations in the primed group (p < 0.001), and that was reflected in higher TNC and CD34 doses per kilogram of recipient in the primed group (p = 0.004 and 0.03, respectively). The OS for primed BM graft recipients was 97.4% and 78.9% for the steady-state BM graft recipients, p-value = 0.01. The cumulative incidence of death without GF was 2.6% in the primed group and 16.3% in the steady-state group, p-value = 0.03. There was no difference in GvHD incidence between the two groups. We confirm that priming improved the TNC and CD34 graft concentration and cell dose; this evidence along with other reported studies constitute reasonable evidence to prove that BM priming improve engraftment. We observed no increase in GvHD using primed BM graft.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:101 |
|---|---|
| Enthalten in: |
Annals of hematology - 101(2022), 2 vom: 01. Feb., Seite 421-428 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
El Fakih, Riad [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Graft |
|---|
| Anmerkungen: |
Date Completed 24.01.2022 Date Revised 24.01.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00277-021-04708-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM332579867 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM332579867 | ||
| 003 | DE-627 | ||
| 005 | 20231225215848.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00277-021-04708-4 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1108.xml |
| 035 | |a (DE-627)NLM332579867 | ||
| 035 | |a (NLM)34719735 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a El Fakih, Riad |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Frontline-matched sibling donor transplant of aplastic anemia patients using primed versus steady-state bone marrow grafts |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.01.2022 | ||
| 500 | |a Date Revised 24.01.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. | ||
| 520 | |a Priming donors with G-CSF before BM harvest is reported to improve engraftment and GvHD in recipients. These effects are highly desirable when transplanting patients with non-neoplastic hematologic diseases, particularly AA patients. Here we retrospectively report the outcomes of 39 AA patients receiving a primed BM graft from MSD to 43 patients receiving a steady-state BM graft from MSD, otherwise transplanted using a uniform transplant platform. The graft had higher TNC and CD34 cell concentrations in the primed group (p < 0.001), and that was reflected in higher TNC and CD34 doses per kilogram of recipient in the primed group (p = 0.004 and 0.03, respectively). The OS for primed BM graft recipients was 97.4% and 78.9% for the steady-state BM graft recipients, p-value = 0.01. The cumulative incidence of death without GF was 2.6% in the primed group and 16.3% in the steady-state group, p-value = 0.03. There was no difference in GvHD incidence between the two groups. We confirm that priming improved the TNC and CD34 graft concentration and cell dose; this evidence along with other reported studies constitute reasonable evidence to prove that BM priming improve engraftment. We observed no increase in GvHD using primed BM graft | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Graft | |
| 650 | 4 | |a MSD | |
| 650 | 4 | |a Mobilized donors | |
| 650 | 4 | |a Primed BM | |
| 650 | 4 | |a SAA | |
| 650 | 4 | |a Steady-state BM | |
| 700 | 1 | |a Alfraih, Feras |e verfasserin |4 aut | |
| 700 | 1 | |a Alhayli, Saud |e verfasserin |4 aut | |
| 700 | 1 | |a Ahmed, Syed Osman |e verfasserin |4 aut | |
| 700 | 1 | |a Shaheen, Marwan |e verfasserin |4 aut | |
| 700 | 1 | |a Chaudhri, Naeem |e verfasserin |4 aut | |
| 700 | 1 | |a Alsharif, Fahad |e verfasserin |4 aut | |
| 700 | 1 | |a Hanbali, Amr |e verfasserin |4 aut | |
| 700 | 1 | |a Alshaibani, Alfadel |e verfasserin |4 aut | |
| 700 | 1 | |a Alotaibi, Ahmad S |e verfasserin |4 aut | |
| 700 | 1 | |a Alharbi, Bander |e verfasserin |4 aut | |
| 700 | 1 | |a AlYahya, Faisal Mohammed |e verfasserin |4 aut | |
| 700 | 1 | |a Rawas, Wedian M |e verfasserin |4 aut | |
| 700 | 1 | |a Ghabashi, Emad |e verfasserin |4 aut | |
| 700 | 1 | |a Kotb, Ahmed |e verfasserin |4 aut | |
| 700 | 1 | |a Elhassan, Tusneem |e verfasserin |4 aut | |
| 700 | 1 | |a Rasheed, Walid |e verfasserin |4 aut | |
| 700 | 1 | |a Alzahrani, Hazzaa |e verfasserin |4 aut | |
| 700 | 1 | |a Almohareb, Fahad |e verfasserin |4 aut | |
| 700 | 1 | |a Alahmari, Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Aljurf, Mahmoud |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of hematology |d 1991 |g 101(2022), 2 vom: 01. Feb., Seite 421-428 |w (DE-627)NLM012918768 |x 1432-0584 |7 nnns |
| 773 | 1 | 8 | |g volume:101 |g year:2022 |g number:2 |g day:01 |g month:02 |g pages:421-428 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00277-021-04708-4 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 101 |j 2022 |e 2 |b 01 |c 02 |h 421-428 | ||